Endourology & Stone Disease(구연) Oral Session 6 / Endourology & Stone Disease (Ⅰ) (O-052) Crystal A (3F) 11월28일(수) 14:00-15:00 미라베그론이 요관부목 환자의 불편감을 줄여줄수 있는가?: 전형적 무작위 다기관 연구 ¹고려대학교 의과대학 안산병원 비뇨의학과 ²인제대학교 일산백병원 비뇨의학과 전병조¹ 태범식¹, 조석², 최훈¹, 박재영¹, 조성용², 이건철², 배재현¹ Objectives: To evaluate the effects of 50 mg once daily mirabegron for ureteral stent-related discomfort after ureteroscopic procedures through a multicenter randomized study. Patients and Methods: One hundred patients with indwelling ureteral stents following ureteroscopic stone removal or retrograde intrarenal surgery (RIRS) were randomized 1:1 to receive either no treatment or mirabegron during the stenting period. At the time of stent removal, the validated Ureteral Stent System Questionnaire (USSQ), International Prostate Symptom Score (IPSS), total amount of analgesics administered, and post voiding residual urine volume were reported for each patient. Results: Overall, 96 patients were enrolled for analysis. The USSQ body pain scores (21.96 vs 13.96, P = 0.007) and overall pain score (5.58 vs 2.83, P = 0.002) were lower in the mirabegron group than in the control group. The USSQ urinary symptom scores (32.58 vs 27.92, P = 0.582) and USSQ general health score (17.71 vs 14.00, P = 0.281) were also lower in the mirabegron group but the difference was not significant. Post-operative IPSS total scores and quality of life scores were lower in the mirabegron group, but the difference was not significant. However, the change of IPSS storage symptom score was lower in the mirabegron group than in the control group (3.58 ± 3.58 vs 1.83 ± 4.39, P = 0.035). The amount of residual urine volume was not different between the two groups (P > 0.05). Conclusion: The use of 50 mg once daily mirabegron has the potential to reduce ureteral stent-related discomfort. Prospective larger-scale, placebo-controlled studies are warranted to further evaluate the beneficial effects of mirabegron on stent-related symptoms. keywords : Mirabegron, Ureteral stent, Discomfort, Pain